Wire · opportunities
Amivantamab-vmjw nears three-year OS in EGFR exon 20 NSCLC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 September 2026 · Fusion42 review
Final Phase 3 PAPILLON trial data reveal that amivantamab-vmjw combined with chemotherapy achieves a median overall survival of 34.3 months in EGFR exon 20 insertion-positive non-small cell lung cancer, nearly double the historical real-world survival. Although the primary overall survival analysis did not reach statistical significance due to high crossover rates, adjusted analyses suggest a substantial survival benefit.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have a new survival benchmark for EGFR exon 20 insertion NSCLC that demands updating your clinical positioning and messaging. This trial opens a door for amivantamab-based first-line combinations despite the statistical hurdles, making it time to engage oncologists early and anticipate tolerability management.
◆ Coverage
1 source · 22 Sep 2026
◆ Related on Wire
◆ Topics